ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has reported promising results from its Phase Ib/IIa clinical trial of IMM0306, a bispecific molecule for treating indolent lymphoma. The trial ...

Monjuvi is available under an accelerated approval to treat adults with relapsed or refractory diffuse large B-cell lymphoma.

At the 42nd Annual Chemotherapy Foundation Symposium, Erin Mulvey, MD, discussed the significant progress being made in the ...

Follicular lymphoma is the most common type, but others include marginal zone, cutaneous T-cell and lymphoplasmacytic ...

Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for cancer based on its unique Mimicry platform, will be holding a webinar to run through new clinical data from the ...

Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal hemoglobinuria Initial results for odronextamab in first ...

Among them are initial results in patients with previously untreated follicular lymphoma from Part 1 of the Phase 3 OLYMPIA-1 confirmatory trial, which consists of a non-randomized safety run-in ...

There’s a famous quote by Friedrich Nietzsche that says “That which does not kill us makes us stronger.” I have follicular ...

Q3 2024 Earnings Call Transcript November 9, 2024 Operator: Good morning, ladies and gentlemen, and welcome to the ADC Therapeutics Third Quarter 2024 Earnings Conference Call. [Operator Instructions] ...

The remaining patients had the following: marginal zone lymphoma (10.9%); follicular lymphoma (2.5%); Burkitt lymphoma (2.2%) ...

LOTIS-5 full enrollment and LOTIS-7 initial efficacy, safety update anticipated by end of 2024 Updated ZYNLONTA® Phase 2 ...

Santa Monica, California Thursday, November 7, 2024, 10:00 Hrs [IST] ...